Abstract:Introduction The purpose of predictive genetic tests is to identify carriers or the onset of a disease in pre-symptomatic individuals. Prediction is linked to a negative psychological impact (anxiety, depression, etc.), depending on the perception of risk, the severity of the disease, and the availability and effectiveness of treatments. Objectives Here, we report on genetic counselling during predictive genetic testing offered to an Arab family affected by fragile X condition (FXS) caused by the unstable expansion of a CGG repeat (CGGR) in the FMR1 gene. Methods A 10-year-old boy who harbored a mental retardation was referred to our genetic counselling for genetic testing as he was suspected to be affected by FXS. Screening of FMR1 gene mutations was conducted for the index case and his mother. A predictive genetic testing for the family members (brothers, sisters and others) was offered, focusing on knowledge of genetics and medical risks of FXS. Results FMR1 molecular analysis showed a full mutation (300 to 2000 CGGR) for the boy and a large premutation (100 CGGR) for the mother. During genetic counselling, the family was informed about the significance of the genetic results. In FXS initiated by an expansion of over 200 CGGR. While mental retarded males usually harbor the full mutation, the mother carry a premutation (70 to 200 CGGR). The deficiency of FMR protein (FMRP) in the neurons of affected males leads to brain developmental abnormalities. Some pre-mutated children may show signs of the autism spectrum disorder and females may develop FMR1-related premature ovarian insufficiency. An increased risk of a late onset fragile X tremor ataxia syndrome is identified in pre-mutated men (55 to 200 CGGR) and less in women. Conclusions The reduction or loss of FMRP leads to multisystem damage. Neuropsychiatric disorders such as mental retardation, speech and language delay, autism spectrum disorder, sensory hyperexcitation, social anxiety, abnormal eye contact, shyness and aggressive behaviour are common in individuals with the mutation. Affected women are often under-diagnosed because mental retardation is not constant, but minor disorders including a borderline IQ with learning difficulties and emotional disturbances have been reported. Conditions associated with fragile X premutation, a term proposed by the European Fragile X Network (FXPAC), seem to be characterized by many physical and psychological health symptoms. Anxiety, depression, sleep disorders and mood disorders are more common in permutated individuals. However, new reports suggested that FXS patients could be at unusually low risk of cancers, because FMRP is over-expressed in multiple cancer tissues. Disclosure of Interest None Declared

A Comprehensive Review of Fragile X Syndrome and Fragile X Premutation Associated Conditions in Africa

Fragile X Syndrome: Prevalence, Treatment, and Prevention in China

Fragile X Syndrome and FMR1 premutation: results from a survey on associated conditions and treatment priorities in Italy

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment

Fragile X Syndrome: A Review for General Pediatricians

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

Consensus Statement of the Indian Academy of Pediatrics on Diagnosis and Management of Fragile X Syndrome in India

Knowledge and perceptions about fragile X syndrome and fragile X‐premutation‐associated conditions among medical doctors in Nigeria

New Targeted Treatments for Fragile X Syndrome

Developmental studies in fragile X syndrome

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence

Epigenetic insights into Fragile X Syndrome

Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation

Fragile X syndrome in children with learning difficulties and the diagnostic dilemma

Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues

Oligodendroglia and myelin pathology in fragile X syndrome

Fragile X Syndrome and Premutation Disorders: New Developments and Treatments

A holistic approach to fragile X syndrome integrated guidance for person‐centred care

Pain and gain of predictive genetic testing: Particular case of fragile X syndrome

Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes

Mechanisms of Genome Instability in the Fragile X-Related Disorders